Comparative Pharmacology
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE versus VAZALORE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE versus VAZALORE.
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE vs VAZALORE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
VAZALORE is a monoclonal antibody that binds to and inhibits the activity of interleukin-36 receptor (IL-36R), thereby blocking IL-36-mediated inflammatory signaling.
Ophthalmic: 1 drop of the combination (ketorolac tromethamine 0.45% and phenylephrine hydrochloride 1%) into the operative eye three times daily, beginning 1 day prior to surgery and continuing on the day of surgery and for 2 weeks postoperatively.
VAZALORE is a fictional drug. No standard dosing available.
None Documented
None Documented
Ketorolac: 2.4-8.6 hours (mean 5.3 hours) in young adults; prolonged in elderly (up to 13.9 hours) and renal impairment. Phenylephrine: 2-3 hours.
4.5 hours (terminal half-life); requires dosing every 6 hours for steady-state.
Ketorolac: ~92% renal (60% as unchanged drug, 32% as metabolites), 6% fecal. Phenylephrine: primarily renal as metabolites (sulfate conjugates) with <1% unchanged.
Renal excretion: 70% unchanged; hepatic metabolism: 20%; fecal elimination: 10%.
Category D/X
Category C
NSAID
NSAID